Novo Nordisk hopes to stabilize Wegovy supply in early 2022

Production of obesity drug Wegovy is still expected to experience delays for the rest of 2021, but should, however, be stabilized in early 2022, the pharmaceutical company reports.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

Novo Nordisk has significantly increased the production of its weight loss drug Wegovy, which is in high demand, and is now hoping to have stabilized its supply early next year, the company writes in an update on its website.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading